Valuation: DiaMedica Therapeutics Inc.

Market Cap 551M 393M 344M 317M 292M 37.88B 563M 3.79B 1.49B 18.55B 1.48B 1.44B 63.87B P/E 2026 *
-8.8x
P/E 2027 * -8.3x
Enterprise Value 551M 393M 344M 317M 292M 37.88B 563M 3.79B 1.49B 18.55B 1.48B 1.44B 63.87B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
56.7%
Yield 2026 *
-
Yield 2027 * -
1 day+2.38%
1 week-4.82%
Current month+3.69%
1 month+27.40%
3 months+6.57%
6 months-3.63%
Current year-8.29%
1 week 6.61
Extreme 6.61
7.78
1 month 5.77
Extreme 5.77
8.52
Current year 5.24
Extreme 5.245
9.04
1 year 4.01
Extreme 4.0145
10.42
3 years 1.94
Extreme 1.9382
10.42
5 years 1.12
Extreme 1.12
10.42
10 years 1.12
Extreme 1.12
13.77
Manager TitleAgeSince
Chief Executive Officer 54 01/01/2010
Director of Finance/CFO 60 01/04/2018
Chief Tech/Sci/R&D Officer - 12/09/2023
Director TitleAgeSince
Director/Board Member 70 10/08/2010
Chairman 54 01/04/2008
Chairman 60 01/01/2025
Date Insider Type Main position Quantity % Market Cap.
1/6/26 Free

Chief Financial Officer

162,000 -
1/6/26 Free

Director

40,412 -
1/6/26 Option

Director

40,412 0.0750%
Change 5-day change 1-year change 3-year change Capi.($)
+2.38%-4.82%+85.75%+78.48% 393M
-7.17%-4.39%+45.51%+79.00% 52.1B
+0.24%-1.54%+53.22%+71.85% 53.83B
+0.80%-6.31%+3.98%+423.29% 23.48B
-0.09%-0.01%-17.62%-14.67% 23.13B
-5.95%-2.58%+30.67%-9.58% 19.36B
-1.14%+0.03%+31.57%-30.42% 17.56B
-5.16%-7.00%+168.44%+306.37% 15.2B
-6.91%-5.83%+26.53%+636.97% 14.83B
+0.43%-1.03%+24.63%+191.40% 14.06B
Average -2.26%-2.84%+45.27%+173.27% 23.39B
Weighted average by Cap. -2.79%-2.36%+40.20%+143.99%

Financials

2026 *2027 *
Net sales - -
Net income -63.21M -45.12M -39.43M -36.38M -33.54M -4.34B -64.61M -435M -171M -2.13B -169M -166M -7.33B -78.02M -55.69M -48.67M -44.91M -41.4M -5.36B -79.75M -537M -211M -2.63B -209M -205M -9.04B
Net Debt - -
Logo DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people suffering from preeclampsia (PE) and acute ischemic stroke (AIS). The Company’s lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of pre-eclampsia, acute ischemic stroke and other vascular diseases. DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1 (rhKLK1) in clinical development for preeclampsia and acute ischemic stroke. KLK1 is a serine protease enzyme that is involved in the regulation of diverse physiological processes via a molecular mechanism that increases the production of nitric oxide, prostacyclin and endothelium-derived hyperpolarizing factors. In the treatment of preeclampsia, DM199 is intended to lower blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta.
Employees
35
Date Price Change Volume
17/07/26 USD 7.300 +2.38% 199,805
16/07/26 USD 7.130 -6.68% 260,029
15/07/26 USD 7.640 +2.83% 161,576
14/07/26 USD 7.430 -0.80% 152,253
13/07/26 USD 7.490 -2.35% 168,130
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
7.300USD
Average target price
15.50USD
Spread / Average Target
+112.33%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DMAC Stock